Influence of mismatch of env sequences on vaccine protection by live attenuated simian immunodeficiency virus

Journal of Virology

Volumn 87, Issue 13, 2013, Pages 7246-7254

  Manrique, Julieta ^a,c   Piatak, Michael ^b   Lauer, William ^a   Johnson, Welkin ^a,d   Mansfield, Keith ^a,e   Lifson, Jeffrey ^b   Desrosiers, Ronald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSIDAD NACIONAL DE LA PATAGONIA SAN JUAN BOSCO   (Argentina)

^d BOSTON COLLEGE   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LIVE VACCINE; NEF PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELETION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NEF GENE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEQUENCE ALIGNMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SUPERINFECTION; VACCINATION; VIROGENESIS; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; BASE SEQUENCE; ENZYME-LINKED IMMUNOSPOT ASSAY; GENE PRODUCTS, ENV; HEK293 CELLS; HUMANS; INTERFERON-GAMMA; MACACA MULATTA; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS, DNA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIRAL VACCINES;

EID: 84880353735     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00798-13     Document Type: Article

References (30)

1. Desrosiers RC. 1999. Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat. Med. 5:723-725.
2. Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J. 2007. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog. 3:e177. doi:10.1371/journal.ppat.0030177.
3. Chohan BH, Piantadosi A, Overbaugh J. 2010. HIV-1 superinfection and its implications for vaccine design. Curr. HIV Res. 8:596-601.
4. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992. Protective effects of a live-attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
5. Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, Glickman R, Yang J, Montefiori DC, Montelaro R, Wyand M, Desrosiers RC. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relation of degree of protection with level of attenuation. J. Virol. 73:4952-4961.
6. Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, Gettie A, Fenamore EA, Sheridan KE, Ho DD, Dailey PJ, Marx PA. 1998. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Virol. 72:7501-7509.
7. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. 1999. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73:8356-8363.
8. Reynolds MR, Weiler AM, Piaskowski SM, Kolar HL, Hessell AJ, Weiker M, Weisgrau KL, Leon EJ, Rogers WE, Makowsky R, McDermott AB, Boyle R, Wilson NA, Allison DB, Burton DR, Koff WC, Watkins DI. 2010. Macaques vaccinated with simian immunodeficiency virus SIVmac239_nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J. Virol. 84:9190-9199.
9. Hirsch V, Adger-Johnson D, Campbell B, Goldstein S, Brown C, Elkins WR, Montefiori DC. 1997. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J. Virol. 71: 1608-1620.
10. Means RE, Greenough T, Desrosiers RC. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71:7895-7902.
11. Abdel-Motal UM, Gillis J, Manson K, Wyand M, Montefiori D, Stefano-Cole K, Montelaro RC, Altman JD, Johnson RP. 2005. Kinetics of expansion of SIV Gag-specific CD8_ T lymphocytes following challenge of vaccinated macaques. Virology 333:226-238.
12. Walsh SR, Gillis J, Peters B, Mothe BR, Sidney J, Sette A, Johnson RP. 2009. Diverse recognition of conserved orthopoxvirus CD8_ T cell epitopes in vaccinated rhesus macaques. Vaccine 27:4990-5000.
13. Cline AN, Bess JW, Piatak M, Jr, Lifson JD. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34:303-312.
14. Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, Mahyari E, Hagen SI, Bae JY, Reyes MD, III, Swanson T, Legasse AW, Sylwester A, Hansen SG, Smith AT, Stafova P, Shoemaker R, Li Y, Oswald K, Axthelm MK, McDermott A, Ferrari G, Montefiori DC, Edlefsen PT, Piatak M, Jr, Lifson JD, Sekaly RP, Picker LJ. 2012. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat. Med. 18:1673-1681.
15. Salisch NC, Kaufmann DE, Awad AS, Reeves RK, Tighe DP, Li Y, Piatak M, Jr, Lifson JD, Evans DT, Pereyra F, Freeman GJ, Johnson RP. 2010. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J. Immunol. 184:476-487.
16. R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
17. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, Desrosiers R. 1990. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248:1109-1112.
18. Regier DA, Desrosiers RC. 1990. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 6:1221-1231.
19. Kestler HW, Ringler DJ, III, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. 1991. Importance of the nef gene for maintenance of high virus loads and for the development of AIDS. Cell 65:651-662.
20. Dyer WB, Ogg GS, Demoitie MA, Jin X, Geczy AF, Rowland-Jones SL, McMichael AJ, Nixon DF, Sullivan JS. 1999. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney blood bank cohort patients infected with nef-defective HIV type 1. J. Virol. 73:436-443.
21. Gauduin MC, Yu Y, Barabasz A, Carville A, Piatak M, Lifson JD, Desrosiers RC, Johnson RP. 2006. Induction of a virus-specific effectormemory CD4_ T cell response by attenuated SIV infection. J. Exp. Med. 203:2661-2672.
22. Lewis MG, Bellah S, McKinnon K, Yalley-Ogunro J, Zack PM, Elkins WR, Desrosiers RC, Eddy GE. 1994. Titration and characterization of two rhesus derived SIVmac challenge stocks. AIDS Res. Hum. Retroviruses 10:213-220.
23. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, O'Connor S, Marx PA, Meythaler M, Goldstein S, Buckler-White A, Kaur A, Hirsch VM, Johnson WE. 2010. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol. 8:e1000462. doi:10.1371/journal.pbio.1000462.
24. Burns D, Collignon C, Desrosiers RC. 1993. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J. Virol. 67:4104-4113.
25. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
26. Cole KS, Rowles JL, Jagerski BA, Murphy-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC. 1997. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol. 71:5069-5079.
27. Ourmanov I, Brown CR, Moss B, Carroll M, Wyatt L, Pletneva L, Goldstein S, Venzon D, Hirsch VM. 2000. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74:2740-2751.
28. Ourmanov I, Kuwata T, Goeken R, Goldstein S, Iyengar R, Buckler-White A, Lafont B, Hirsch VM. 2009. Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4_ T-cell loss and higher titers of neutralizing antibody. J. Virol. 83:5388-5400.
29. Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, Bett A, Schleif WA, Liang X, Flynn J, Tobery TW, Wilson K, Finnefrock A, Huang L, Vitelli S, Lin J, Patel D, Davies ME, Heidecker GJ, Freed DC, Dubey S, O'Connor DH, Watkins DI, Zhang ZQ, Shiver JW. 2010. Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J. Virol. 84:2996-3003.
30. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93.